Premium
P2–002: Levels and turnover of endogenous APP metabolites in the wild–type mouse brain
Author(s) -
Mazzella Matthew J.,
Diaz Nichole S.,
Berger Jason,
Mathews Paul M.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.839
Subject(s) - cycloheximide , amyloid precursor protein , genetically modified mouse , western blot , immunoprecipitation , metabolite , biology , protein turnover , endogeny , microbiology and biotechnology , wild type , transgene , endocrinology , medicine , chemistry , biochemistry , gene , alzheimer's disease , protein biosynthesis , mutant , disease
upon symptoms in the Mood cluster at both weeks 12 (P .034) and 24 (P .033), with 65.5% of patients in the memantine group showing a positive response at week 24. Memantine also had a significant effect over placebo (OC) upon symptoms of Psychosis at both weeks 12 (P .006) and 24 (P .001), with 80.7% of patients in the memantine group showing a positive response in this domain at week 24. The response difference (OC) between memantine and placebo patients at week 24 was 12.2% and 18.9% for Mood and Psychosis clusters, respectively. LOCF analysis yielded comparable results. Effects of memantine on Frontal symptoms were not significant, while the effects on Other symptoms were significant at week 24 using LOCF analysis (P .037), but not OC analysis (P .058). Conclusions: Taken together, these results suggest that memantine provides specific behavioral benefits for mood and psychosis-related symptoms associated with AD.